Viral

Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

Retrieved on: 
Thursday, February 8, 2024
Research, Immune system, Immunotherapy, Patient, Social media, Therapy, Viral, Education, Cancer, Pharmaceutical industry

Recognizing the importance of engaging with all stakeholders, Indaptus will generate content on a variety of digital platforms, including X (formerly known as Twitter) and LinkedIn.

Key Points: 
  • Recognizing the importance of engaging with all stakeholders, Indaptus will generate content on a variety of digital platforms, including X (formerly known as Twitter) and LinkedIn.
  • Jeffrey Meckler, Indaptus Therapeutics’ CEO, expressed enthusiasm about this initiative, stating, "Our goal is not only to advance groundbreaking treatments, but also to foster open communication and education around our work.
  • Social media provides an ideal platform for connecting with a broader audience, sharing insights, and building a community that is passionate about medical advancements."
  • The launch of these channels signifies Indaptus Therapeutics' commitment to transparency, knowledge-sharing, and a desire to stay connected with its stakeholders.

Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections

Retrieved on: 
Wednesday, February 7, 2024
CD34, Infrared spectroscopy correlation table, COVID-19, Cell, Immune system, World Health Organization, NK, Patient, CRS, Safety, AML, Virus, Hospital, COVID, FDA, Death, CDC, MDS, Cytokine release syndrome, HSPC, Therapy, Vaccination, Master of Science, RSV, Infection, Viral, Physician, Cancer, Epidemic, Vaccine

WEXFORD, Pa., Feb. 7, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer and infectious diseases, today announced plans to pursue DVX201, its proprietary allogeneic stem cell expansion and directed differentiation platform of unmodified natural killer (NK) cell therapy, as an antiviral treatment addressing various respiratory viral infections that lead to hospitalization, including the "tripledemic" of influenza, COVID-19 and respiratory syncytial virus (RSV).

Key Points: 
  • DVX201 is produced by pooling CD34+ cells isolated from multiple cord blood donations to increase lot size and immune system diversity.
  • Importantly, doses undergo stringent testing including a potency assay before treatment, to assess their ability to kill virally infected cells.
  • Additionally, DVX201 does not contain T-cells, which significantly reduces the possibility for major rejection by patients, which is a major concern for some cell therapy products.
  • DVX201, the first-ever allogeneic, cord-blood derived NK cell therapy generated from pooled donor CD34+ HSPC cells, has the potential to offer significant support to patients and to our strained healthcare system."

BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections

Retrieved on: 
Wednesday, February 7, 2024
IL-8, COVID-19, Inflammation, Cytokine, Urinary tract infection, Downregulation and upregulation, MD, Therapy, Patient, University, Lung, Rhinovirus, Acute respiratory distress syndrome, Protein, RSV, Infection, Neutrophil, Blood, AXL, IL-6, Viral

The data presented by Dr. Spalluto showed bemcentinib had activity in human in vitro models of infection caused by Respiratory Syncytial Virus (RSV), influenza and rhinovirus.

Key Points: 
  • The data presented by Dr. Spalluto showed bemcentinib had activity in human in vitro models of infection caused by Respiratory Syncytial Virus (RSV), influenza and rhinovirus.
  • In these models, bemcentinib downregulated IL-6 and IL-8, two important inflammatory cytokines associated with the severity of hospitalized respiratory infections.
  • Clinically, patients with viral respiratory infections can develop acute respiratory distress syndrome (ARDS), a life-threatening condition.
  • We look forward to conducting additional preclinical evaluation of bemcentinib's activity in severe respiratory infections to further bolster our understanding in this important area."

BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections

Retrieved on: 
Wednesday, February 7, 2024
IL-8, COVID-19, Inflammation, Cytokine, Urinary tract infection, Downregulation and upregulation, MD, Therapy, Patient, University, Lung, Rhinovirus, Acute respiratory distress syndrome, Protein, RSV, Infection, Neutrophil, Blood, AXL, IL-6, Viral

The data presented by Dr. Spalluto showed bemcentinib had activity in human in vitro models of infection caused by Respiratory Syncytial Virus (RSV), influenza and rhinovirus.

Key Points: 
  • The data presented by Dr. Spalluto showed bemcentinib had activity in human in vitro models of infection caused by Respiratory Syncytial Virus (RSV), influenza and rhinovirus.
  • In these models, bemcentinib downregulated IL-6 and IL-8, two important inflammatory cytokines associated with the severity of hospitalized respiratory infections.
  • Clinically, patients with viral respiratory infections can develop acute respiratory distress syndrome (ARDS), a life-threatening condition.
  • We look forward to conducting additional preclinical evaluation of bemcentinib's activity in severe respiratory infections to further bolster our understanding in this important area."

Viral Sensitizers Market Research Report 2023: Viral Vaccines, Oncolytic Viral Therapies and Viral Vectors - Global Industry Trends and Forecasts, 2020-2022 and 2023-2035 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 6, 2024
Health, Oncology, Other Health, Science Advisory Board, COVID-19, Genetic engineering, Workflow, Cell, Vector (mathematics and physics), Government, MLD, Cold medicine, Tetanus, Patient, DTP, Virus, COVID-19 vaccine, FDA, World Health Organization, AAV, Cell death, Vaccine, Infection, Measles, Gene, Viral, GMP, Immunization, WHO

The "Viral Sensitizers Market: Distribution by Application Area (Viral Vaccines, Oncolytic Viral Therapies and Viral Vectors) and Key Geographical Regions (North America, Europe and Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2023-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Viral Sensitizers Market: Distribution by Application Area (Viral Vaccines, Oncolytic Viral Therapies and Viral Vectors) and Key Geographical Regions (North America, Europe and Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2023-2035" report has been added to ResearchAndMarkets.com's offering.
  • The market research report highlights the efforts of several stakeholders engaged in this rapidly evolving segment of the viral manufacturing industry.
  • Key takeaways of the viral sensitizers market report are briefly discussed below.
  • We have extensively studied the historical market data within this industry, in order to develop a deeper understanding of the evolutionary market trends.

EQS-News: AATec Medical starts collaboration with the German Federal Agency for Disruptive Innovation SPRIND for alpha-1 antitrypsin

Retrieved on: 
Tuesday, February 6, 2024
Partnership, Alpha-1 antitrypsin deficiency, Research, Inflammation, Lung, Acute respiratory distress syndrome, COPD, AAT, Innovation, Viral, Asthma, Pharmaceutical industry

This project is a key step in the development of the innovative ATL-105 drug platform for the treatment of respiratory diseases.

Key Points: 
  • This project is a key step in the development of the innovative ATL-105 drug platform for the treatment of respiratory diseases.
  • As part of the collaboration with SPRIND, ATL-105 will be tested in various disease models for viral diseases of the respiratory tract.
  • Sigrid Koeth, Innovation Manager at SPRIND, emphasizes the importance of the project: "With SPRIND, we want to create disruptive innovations from Germany.
  • Dr. Rüdiger Jankowsky, co-founder and CEO of AATec, comments on the collaboration: "The partnership with SPRIND enables us to accelerate our research and development work and realize our innovation potential faster.

ALLOVIR, INC. (NASDAQ: ALVR) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against AlloVir, Inc.

Retrieved on: 
Tuesday, February 6, 2024
Research, Action Replay, News, Patient, Virus, District court, Advertising, Defendant, Complaint, Viral, Court, Security (finance)

If you purchased or acquired AlloVir securities, and/or would like to discuss your legal rights and options please visit AlloVir, Inc.

Key Points: 
  • If you purchased or acquired AlloVir securities, and/or would like to discuss your legal rights and options please visit AlloVir, Inc.
  • If you wish to serve as lead plaintiff, you must move the Court no later than March 19, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

ALVR Stock News: Investors with Large Losses Should Contact Robbins LLP for Information About the Class Action Against AlloVir, Inc.

Retrieved on: 
Tuesday, February 6, 2024
Class Action Lawsuit, Professional Services, Legal, News, Research, Patient, LLP, Viral, Virus, Complaint, Person, Vaccine

For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.

Key Points: 
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • Specifically, AlloVir said it was discontinuing the posoleucel Phase 3 studies after pre-planned analyses concluded they wouldn’t meet their primary endpoints.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against AlloVir, Inc. Shareholders who want to act as lead plaintiff for the class should contact Robbins LLP.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Memo Therapeutics AG Strengthens Management Team

Retrieved on: 
Monday, February 5, 2024
Leiden University, Bachelor of Science, Supply chain management, CMC, Chemistry, Wageningen University & Research, PPD, Maartje (name), Master of Science, MTX, AbbVie, Barton College, Doctor of Philosophy, Viral, Nursing, Pharmaceutical industry

Ms. Clemmer is an accomplished global clinical research leader with over 20 years of experience directing international clinical operations.

Key Points: 
  • Ms. Clemmer is an accomplished global clinical research leader with over 20 years of experience directing international clinical operations.
  • Ms. Clemmer previously held senior leadership positions at the Contract Research Organizations PRA Health Sciences and PPD.
  • She joins MTx from AM-Pharma, where she was responsible for all drug substance activities including Phase III clinical manufacturing.
  • Eric van den Berg, CEO of MTx, commented: “It is a pleasure to welcome Kristie and Maartje to MTx.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir, Inc. of Class Action Lawsuit and Upcoming Deadlines – ALVR

Retrieved on: 
Saturday, February 3, 2024
Pomerantz, Ext, Clinical research associate, Research, News, Patient, Virus, Prior, District court, Action Replay, Complaint, LLP, Viral, Court, Person

NEW YORK, Feb. 03, 2024 (GLOBE NEWSWIRE) --  Pomerantz LLP announces that a class action lawsuit has been filed against AlloVir, Inc. (“AlloVir” or the “Company”) (NASDAQ: ALVR).

Key Points: 
  • NEW YORK, Feb. 03, 2024 (GLOBE NEWSWIRE) --  Pomerantz LLP announces that a class action lawsuit has been filed against AlloVir, Inc. (“AlloVir” or the “Company”) (NASDAQ: ALVR).
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.